Banque Transatlantique’s Vertex Pharmaceuticals VRTX Stock Holding History

Banque Transatlantique’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	507 +42	+9%	+$18.6K	0.01%	279
2026 Q1	$208K	Sell	465 -74	-14%	-$34.5K	0.01%	251
2025 Q4	$244K	Sell	539 -75	-12%	-$32.3K	0.01%	114
2025 Q3	$240K	Sell	614 -162	-21%	-$67.7K	0.01%	114
2025 Q2	$346K	Sell	776 -48	-6%	-$22.1K	0.01%	99
2025 Q1	$399K	Buy	824 +212	+35%	+$98.8K	0.01%	94
2024 Q4	$248K	Buy	+612	New	+$284K	0.01%	112

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Banque Transatlantique's VRTX Position: Q2 2026 in Review

Banque Transatlantique increased its Vertex Pharmaceuticals (VRTX) stake by 9% in Q2 2026, buying an estimated $18.6K and bringing the position to 507 shares worth $246K. The position accounts for 0.01% of the portfolio, ranked #279.

Banque Transatlantique first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $399K in Q1 2025. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Banque Transatlantique held 507 shares of Vertex Pharmaceuticals worth $246K as of Q2 2026.
Banque Transatlantique bought 42 Vertex Pharmaceuticals shares in Q2 2026, an estimated $18.6K.
Vertex Pharmaceuticals made up 0.01% of Banque Transatlantique's portfolio in Q2 2026, its #279 holding.
Banque Transatlantique first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Banque Transatlantique's Vertex Pharmaceuticals position peaked at $399K in Q1 2025.
1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.